U.S. Contraceptive Market Size, Share, Growth Analysis, By Product(Pills, Intrauterine Devices (IUD) (Hormonal IUD, Nonhormonal IUD ), Condoms (Male Condoms), By Age-group(15-44 years, above 44 years), By End-User(Households, clinics, Hospitals), By Region - Industry Forecast 2024-2031

US Contraceptive Market Driver

• The introduction of more effective male contraception products is expected to boost contraceptive sales. Female contraceptives are currently the market leaders, but male contraceptives will see increased demand due to the increased use of male condoms.

Condom use is increasing due to its dual role in birth control and the prevention of sexually transmitted diseases (STD). Furthermore, it has little to no side effects on the body.

Unmet needs among women of reproductive age in developing countries include limited access to contraception, a limited choice of methods, social and religious issues, poor quality of available services, and gender-based barriers. All of these unmet needs can increase the likelihood of unintended pregnancy. As a result, manufacturers are aiming to expand their products and services across developing economies to improve sales

US Contraceptive Market Restraint

• Birth control pills and devices, particularly progestin-only pills, can cause spotting or bleeding between periods, as well as sore breasts, nausea, and headaches. In rare cases, blood clots in the legs, heart attacks and strokes, liver disorders, and gallbladder disease are all serious side effects. During the forecast period, these contraceptive-related side effects will limit sales. Misinformation, a lack of social acceptance, and exaggerated concerns about the safety of contraceptive methods are also significant barriers to contraceptive use.

Furthermore, oral contraceptives increase the risk of heart disease. IUDs are effective contraception; however, in some high-risk individuals, they increase the risk of infection. Although barrier contraception is less effective than other forms of contraception, it does protect against sexually transmitted infections such as HIV. Because of differences in the prevalence of the disorders involved, the value of non-contraceptive benefits and contraceptive risks varies by country